ORM PTO-1	449/A a	nd B (Modif	ied)	1	APPLICATION NO.: 09/669,187	ATTY. I	DOKE LAGE (A)	9/7035
	-L' \		SCLOSURE	[I	FILING DATE: September 25, 2000		V I III	
	1.1	NI BY A	APPLICANT		APPLICANT: Krieg et al.		- 30N X 9 71	וטנ
JUN 1 4 201	<u> </u>	1 -6			GROUP ART UNIT: 1646	EXAM	GH CENTER 160	0/2900
heet IRADE	ART	of	1			<u> </u>		
4 TANDS				U.S	. PATENT DOCUMENTS			
Examiner's	Cite				Name of Patentee or Applicant of Cited		Date of Publication	
nitials#	No.	1	Number	Kind Code	Document		MM-DD-1	
		 						
		+						
	 -	 -			 			
		+						
				FORE	IGN PATENT DOCUMENTS			
Examiner's	Cite	For	eign Patent Docur	nent	Name of Patentee or Applicant of	Cited	Date of	Townslass
nitials#	No.	Office/ Country	Number	Kind Code	Document (not necessary)		Publication of Cited Document MM-DD-YYYY	Translatio (Y/N)
DB	Bl	WIPO	WO98/40100	Al			09-17-1998	
DB DB	B2 B3	WIPO	WO99/58118 WO99/61056	A2 A2			11-18-1999 12-02-1999	
<u> </u>			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				12 02 1777	
	 	<u> </u>						
					N PATENT LITERATURE DOCUMEN			
Examiner's nitials#	Cite No		ook, magazine, jo	urnal, ser	ITAL LETTERS) title of the article (whe ial, symposium, catalog, etc.), date, relevant blisher, city and/or country where publis	ant page(s		Translatio (Y/N)
7.0	C14	LIPFORI	GB et al., CpG-	containin	g synthetic oligonucleotides promote B class of vaccine adjuvants. Eur J Immu.	and cyto	toxic T cell	
UB	(14	4.	to protein antige	ai. a new	ciass of vaccine adjuvants. Eur 3 immu	nui. 1797	Sep,27(9).2340-	
		l						
EXAMINER	Far	Il Bl	chul		DATE CONSIDERED	6/17	104	
	itial if ref	erence conside			conformance with MPEP 609; Draw line through	r citation if r	not in conformance and	not considere
					bmitted to the office in a prior application, Serial ntinuation-in-part, and divisional applications).	l No	, filed	, an
	n, unless	the earlier a			nation listed, even if it was previously submitte IS and is relied upon for an earlier filing date t			

FEB 0 1 2004 W

FORM PTC)-1449/A and B (N	10 tie	d) At A	APPLICATION NO.:	09/669,187	ATTY. DOCKET NO.: C1039.70035US00
	P-1449/A and B (M RMATION I			FILING DATE: Sept	ember 25, 2000	CONFIRMATION NO.; 2999
STATEMENT BY APPLICANT				APPLICANT:	Arthur M. Krieg	
				GROUP ART UNIT:	1642	EXAMINER: David J. Blanchard
Sheet	1	of	1		1042	DAMMADIC DUVIS J. Dianomas

		·	U.S. P	ATENT DOCUMENTS		
Examiner's Initials	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or of issue	
	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY	
					-	
			:	•	•	

FOREIGN PATENT DOCUMENTS Date of Foreign Patent Document Name of Patentee or Applicant of Cited Cite Translation Examiner's Publication of Document No. Office/ Kind Cited Document (Y/N) Initials Number (not necessary) MM-DD-YYYY Country Code 09-21-2000 **B**36 WO 00/54803 A2 Panacea Pharmaceuticals, LLC B37 wo 00/75304 Αl **Aventis Pasteur** 12-14-2000 Abstract

Examiner's Initials	Cite No	OTHER ART — NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
			*

EXAMINER	P1	DA	TE CONSIDERED	5/11	
Tany 1	Juni			1/04	

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PLAPELICANT Sheet I GROUP ART UNIT: 1642 EXAMINER: Blanchard, David J. U.S. PATENT DOCUMENTS Cite No. Number Kind Code No. Number Name of Patentee or Applicant of Cited Date of Publication or of issue of Cited Document MM-DD-YYYY	FORM PTO-1	449/A an	d B (Modifie	ed)	APPLICA	TION NO.: 09/669,187	ATTY. DOC	KET NO.: C1039.70	035US0	0	
Sheet I GROUP ART UNIT: 1642 EXAMINER: Blanchard, David J. Cite No. Number Kind Code Number Code Cited Name of Patentee or Applicant of Cited Number MM-DD-YYYY	INFOR	MATI(ON DISC	LOSURE	FILING D	FILING DATE: September 25, 2000 CONFIRMA			TION NO.: 2999		
Sheet 1					APPLICA	APPLICANT: Krieg et al.				\neg	
Sheet I U.S. PATENT DOCUMENTS Examiner's Initials No. Number Kind Code FOREIGN PATENT DOCUMENTS Examiner's Cite No. Number Code FOREIGN PATENT DOCUMENTS Examiner's Cite Foreign Patent Document Name of Patentee or Applicant of Cited Document MM-DD-YYYY FOREIGN PATENT DOCUMENTS Examiner's Cite Foreign Patent Document Name of Patentee or Applicant of Cited Document Of Cited Document (YN) Examiner's No. Office/ Number Kind (not necessary) Examiner's Name of Patentee or Applicant of Cited Document (YN) Examiner's No. Office/ Number Kind (Not necessary)			/		GROUP A	GROUP ART UNIT: 1642 EXAMIN		FR: Blanchard David I			
Examiner's Initials No. Number Name of Patentee or Applicant of Cited Date of Publication or of issue of Cited Document Name of Patentee or Applicant of Cited Document MM-DD-YYYY	Sheet 1		GA APROV	444 3							
FOREIGN PATENT DOCUMENTS Examiner's Initials No. Office/ Number Kind (not necessary) FOREIGN PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document (Y/N) Name of Patentee or Application of Cited Document (Y/N) Office/ Number Kind (not necessary)		· · · · · ·	L Spani	TMBB XX	U.S. P	PATENT DOCUMENTS					
FOREIGN PATENT DOCUMENTS Examiner's Initials No. Office/ Number Kind (not necessary) FOREIGN PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document (Y/N) Name of Patentee or Application of Cited Document (Y/N) Office/ Number Kind (not necessary)		Cite No.	1	.S. Patent Docum	Kind Code		of Cited Doc		ocument		
Examiner's Initials No. Office/ Number Kind Name of Patentee or Applicant of Cited Document (Y/N) Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N)					Code						
Examiner's Initials Cite No. Office/ Number Kind Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N) Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N)											
Examiner's Initials Cite No. Office/ Number Kind Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N) Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N)											
Examiner's Initials Cite No. Office/ Number Kind Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N) Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N)											
Examiner's Initials Cite No. Office/ Number Kind Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N) Name of Patentee or Applicant of Cited Publication of Cited Document (Y/N)											
Examiner's Initials No. Office/ Number Kind Name of Patentee or Applicant of Cited Document (Y/N) Name of Patentee or Applicant of Cited Document (Y/N) Office/ Number Kind (not necessary)					FOREIG	N PATENT DOCUMENTS					
Initials No. Office/ Number Kind (not necessary) Cited Document (Y/N)	Examiner's	Cite	Cite Foreign Patent Docum		ment			Publication of Translation		ation	
		No.		Number					(Y/I	4)	
•											
Examiner's Cite Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item Translatio	Examiner's	Cite	Include	OTHER A	ART — NON	PATENT LITERATURE DOCU	UMENTS when appropriate), title of the item	Transla	tion	
Initials No (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.			(book, n	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),					(Y/I	N)	
C97 GOUKASSIAN et al., "Topical DNA Oligonucleotide Therapy Reduces UV-induced Mutations and Photocarcinogenesis in Hairless Mice", PNAS, 101(11): 3933-3938, 2004.	DB	C97	GOUKASS Photocarcia	OUKASSIAN et al., "Topical DNA Oligonucleotide Therapy Reduces UV-induced Mutations and							
EXAMINER DATE CONSIDERED / /	EXAMINER		1	-1	7	DATE CONSIDERE	ED / /				
Famil Block DATE CONSIDERED 6/17/04		Fan	nel L	Eleh			6/17/0	4			

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

•a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

		MAY 2 4 2004	الم الم						
FORM PTO	O-1449/A an		P.	ATION NO.: 09/669,187	ATTY. DOC	KET NO.: C1039.70	035US00		
INFO	RMATI	d B (Modifile) ON DISCLOSURE F BY APPLICANT	FILING	FILING DATE: September 25, 2000 CONFIRMAT			TION NO.: 2999		
STAT	remen1	BY APPLICANT	APPLICA	APPLICANT: Krieg et al.					
Sheet	1	of 1	GROUP	GROUP ART UNIT: 1642 EXAMINER: David J. I			Blanchard		
·	<u></u>		II S	PATENT DOCUMENTS	<u> </u>				
P	Cite	U.S. Patent Docur		Name of Patentee or Applica	nt of Cited	Date of Publication			
Examiner's Initials	No. Number		Kind Code	Document		of Cited Doo MM-DD-Y			
•									
					· · · · · · · · · · · · · · · · · · ·				
	·			GN PATENT DOCUMENTS	4 - 6 0 2 - 4	Date of			
Examiner's Initials	Cite No.	Office/ Country Number	Kind Code	Kind Document		Publication of Cited Document MM-DD-YYYY	Translation (Y/N)		
			<u> </u>				·		
Examiner's Initials	s Cite	Include name of the auth	or (in CAPIT.	N PATENT LITERATURE DOCU AL LETTERS) title of the article (vosium, catalog, etc.), date, relevant	vhen appropriate page(s), volume	e), title of the item >-issue number(s),	Translation (Y/N)		
TS	publisher, city and/or country where published. C97 BOHLE et al. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.								
41									
						 			
			,						
EXAMIN	IER	. 1011		DATE CONSIDERE	٠// ا	1611			

ara ang manakang kang kalang manakang PON ING Salah mang kang kang kang Kalang kang kang manang kang manakang

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. nelude copy of this form with next communication to applicant.

a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier illing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier pplication, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier pplication.]

DIPE 1015

Sheet

FORM PTO-14/9/A and B (Modified)

TAFFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 4

APPLICATION NO.: 09/669,187

ATTY. DOCKET NO.: C01039.70035.US

FILING DATE: September 25, 2000

CONFIRMATION NO.: 2999

APPLICANT:

Arthur M. Krieg, et al.

GROUP ART UNIT: 1633

EXAMINER: James Martinell

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Docum	ent	Name of Patentee or Applicant of Cited	Date of Publication or of issue of Cited Document
Initials	No.	Number	Kind Code	Document	MM-DD-YYYY
DR	Al	5,023,243		Tullis	06-11-1991
	A2	5,248,670		Draper, et al.	09-28-1993
	A3	5,268,365		Rudolph, et al.	12-07-1993
	A4	5,445,938		Hanai, et al.	08-29-1995
	A5	5,488,039		Masor, et al.	01-30-1996
	A6	5,491,088		Hellstrom, et al.	02-13-1996
	A7	5,492,899		Masor, et al.	02-20-1996
	A8	5,585,479		Hoke, et al.	12-17-1996
	A9 -	5,589,466		Felgner, et al.	12-31-1996
	A10	5,591,721		Agrawal, et al.	01-07-1997
	A11	5,602,109		Masor, et al.	02-11-1997
	A12	5,612,060		Alexander	03-18-1997
 	A13	5,663,153		Hutcherson, et al.	09-02-1997
	A14	5,679,647		Carson, et al.	10-21-1997
	A15	5,700,590		Masor, et al.	12-23-1997
	A16	5,705,385		Bally, et al.	01-06-1998
	A17	5,723,130		Hancock, et al.	03-03-1998
	A18	5,723,335		Hutcherson, et al.	03-03-1998
	A19	5,756,097		Landucci, et al.	05-26-1998
	A20	5,780,448		Davis	07-14-1998
	A21	5,786,189		Locht, et al.	07-28-1998
	A22	5,804,566		Carson, et al.	09-08-1998
	A23	5,830,877		Carson, et al.	11-03-1998
	A24	5,837,243		Deo, et al.	11-17-1998
	A25	5,849,719		Carson, et al.	12-15-1998
	A26	5,965,542	}	Wasan, et al.	10-12-1999
	A27	5,976,567		Wheeler, et al.	11-02-1999
	A28	5,981,501		Wheeler, et al.	11-09-1999
	A29	5,985,847		Carson, et al.	11-16-1999
	A30	6,013,639		Peyman, et al.	01-11-2000
	A31	6,027,726		Ansell	02-22-2000
	A32	6,110,745		Zhang, et al.	08-29-2000
	A33	6,174,872		Carson, et al.	01-16-2001
	A34	6,194,388	BI	Krieg, et al.	02-27-2001
./	A35	6,207,646	Bl	Krieg, et al.	03-27-2001
V	A36	6,214,806	BI	Schwartz, et al.	04-10-2001
DR	A37	6,218,371	BI	Krieg, et al.	04-17-2001

679747.1

Tamel Bull

6/17/04

R 0 7 2003	·) .	•			
DB &	A38	6,239,116	BI	Krieg, et al.	05-29-2001
101	A39	6,339,068	BI	Davis, et al.	01-15-2002
TRAIN	A40	6,406,705	B1	Davis, et al.	06-18-2002
V	A41	6,429,199	BI	Krieg, et al.	08-06-2002
DB	A42	2002/0064515	Al	Davis, et al.	05-30-2002

FOREIGN PATENT DOCUMENTS Date of Name of Patentee or Applicant of Cited Foreign Patent Document Translation Publication of Cite Examiner's Document Cited Document (Y/N) Office/ Kind No. Initials Number (not necessary) MM-DD-YYYY Code Country New England Medical Center Hospitals, 03-16-1994 **B4** EP 0 302 758 Bl EP 01-29-1992 Mitsui Toatsu Chemicals, Inc. **B5** 0 468 520 A2 wo 91/12811 Αl Isis Pharmaceuticals, Inc., Et Al. 09-05-1991 **B6** 03-05-1992 Isis Pharmaceuticals, Inc. **B7** WO 92/03456 ΑI The Salk Institute For Biological Studies, 92/18522 A1 10-29-1992 **B8** wo 12-10-1992 A1 Genta Incorporated **B9** WO 92/21353 Αi Isis Pharmaceuticals, Inc. 09-15-1994 94/19945 **B10** WO The Regents Of The University Of CA 03-02-1995 Αl **B11** WO 95/05853 Isis Pharmaceuticals, Inc. 10-05-1995 95/26204 Αl **B12** WO The University Of Iowa Research 02-01-1996 **B13** WO 96/02555 Αl Foundation 05-09-1996 The Regents Of The University Of CA **B14** WO 96/13277 A1 The Regents Of The University Of CA 05-17-1996 96/14074 A1 B15 WO 08-15-1996 ICN Pharmaceuticals, Inc. **B16** WO 96/24380 Αl 11-14-1996 96/35782 A١ Applied Research Systems, et al. **B17** WO 04-09-1998 The Regents Of The University Of CA B18 WO 98/14210 A1 The Regents Of The University Of CA 04-23-1998 Αl 98/16247 **B19** WO The University Of Iowa Research 05-07-1998 **B20** WO 98/18810 Αl Foundation 07-09-1998 98/29430 Ál WO Tam B21 11-19-1998 **B22** wo 98/51278 A2 Inex Pharmaceuticals Corporation Dynavax Technologies Corporation 12-10-1998 A2 **B23** WO 98/55495 The Regents Of The University Of CA 12-10-1998 **B24** WO 98/55609 Αl A١ Inex Pharmaceuticals Corporation 07-08-1999 wo 99/33493 B25 10-21-1999 Smithkline Beecham Biologicals S.A., **B26** WO 99/52549 Αl **Dynavax Technologies Corporation** 12-09-1999 99/62923 A2 **B27** wo Inex Pharmaceuticals Corporation 01-27-2000 00/03683 A2 **B28** WO 00/14217 A2 CPG Immunopharmaceuticals Gmbh 03-16-2000 wo **B29** 03-30-2000 00/16804 A1 Dynavax Technologies Corporation **B30** WO The Regents Of The University Of CA wo 00/20039 Αl 04-13-2000 B31 Dynavax Technologies Corporation 04-20-2000 00/21556 A1 **B32** WO **B33** WO 00/62787 ΑI The Regents Of The University Of CA 10-26-2000 01-11-2001 01/02007 A1 The Regents Of The University Of CA **B34** WO

		OTHER ART — NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item	Translation
Initials	No	(book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s),	(Y/N)
	1	publisher, city and/or country where published.	

Dynavax Technologies Corporation

02-22-2001

679747.1 Taril Blild

B35

wo

01/12223

A2

PA	U, 50,154			elikis, markitalish disebili	المستشائد المساد
	· . 'c' ₃	\ .			
7 7	2003	.\ .\			
DP	8	C15	AGRAWAL, et al., Clin. Pharmacokinet, 28(1):7-16, 1995		
	, ou	C16	AGRAWAL, Tibtech, 14:376-387, 1996		
**		C17	ARKWRIGHT, et al. J Allerg Clin Immunol. 107:531-4, 2001		
		C18	AZAD, et al., Antimicrobial Agents and Chemotherapy, 37:1945-1954, (1993)		
T		C19	AZUMA, et al., Kekkaku, 67(9):625-631, (45-55) 1992		
T		C20	BALLAS, et al., J Immunol 157(5):1840-5, 1996		
\top		C21	BATES, et al. J Biol Chem 274:26369-77, 1999		
		C22	BENIMETSKAYA, et al. Nucleic Acids Res. 25:2648-2656, 1997		
1		C23	BISHOP, et al. J.Biol. Chem. 271:5698-5703, 1996		
T		C24	BLAXTER et al., Mol. and Biochem. Parasitology, 77:77-93		
7		C25	BRANDA et al., Biochemical Pharmacology, 45(10):2037-2043, 1993		
\top		C26	BRANDA, et al., J. Lab Clin Med 128(3):329-38, 1996		
十		C27	BROIDE & RAZ Intl Arch Allerg & Immunol. 118:453-456, 1999		
7		C28	BRUNNER, et al., J Immunol. 165:6278-6286, 2000		T
7		C29	BURGESS, et al., Proc. Natl. Acad. Sci USA 92(9):4051-5, 1995		T
7		C30	CARTER, et al. Intl J Immunopharmacol. 13:69-76, 1991		T
+		C31	CHACE, et al., Clinical Immunology and Immunopathology, (1993), 68(3):327-332		1
+		C32	CONSTANT, et al., Annu. Rev. Immunol., 15:297-322, 1997		1
\dashv		C33	CONSTANT, et al., Science, 264:267-70, 1994		1
\dashv		C34	COWDERY, et al., J Immunol 156(12):4570-5, 15 1996		\top
+		C35	COWSERT, et al. Antimicrobial Chemother. 37:171-77, 1993		+
+		C36	DAPIC, et al. Proc. AACR, pp. 42, March 2001		+
+		C37	DIAMANSTSTEIN, et al. Euro J Immunol. 8:896, 1978		十
+		C38	ELKINS, et al. J. Immunol. 162:2291-2298, 1999		+
╅		C39	EWEL, et al., Cancer Res., 52(11):3005-10, 1992		+
+		C40	FUJIEDA, et al., Anticancer Res., 12:1941-1946, 1992		+-
+		C41	GAO, et al., Mol. Pharmacol. (1992), 41, 223-229		+
+		C42	GOLD, et al., Annual Rev. Biochem. 64:763-97, 1995.		+
╁		C43	HADDEN J et al., JAMA, (1992) 268:20:2964-2969		+
╀		C44	HADDEN J et al., TIPS, (1993), 141:169-174		+
╀		C45	HAHM, et al. Intl J. Immunopharmacol. 16:217, 1994		+-
+		C46	HALPERN MD et al., Cell Immunol 167(1):72-8, 1996		+
╀		C47	HARRINGTON, et al. Infection Immunity 24:160, 1970	-+-	+
╀		C48	HARTMANN, et al. Antisense Nucleic Acid Drug Dev, 6:291, 1996		+
+		C49	HATZFELD J., J. Exp. Med., (1991) 174:925-929		+
+		C50	HERTL, et al., J. Invest. Dermatol., 104:813-818, 1995.		+
╀		C51	HORNER, et al. Springer Semin Immunophathol, 22(1-2):133-46, 2000		+
+		C52	HORSPOOL, et al., J. Immunol, 160, 2706-2714, 1998		+
+		C52	HUANG, et al., Infection and Immunity, 67(12):6257-6263 (1999)		+
+		C54	HUGHES, et al. Antisense Res Dev 4:211-15, 1994	 	+
+		C55	ISHIKAWA, et al., J Immunol 150(9):3713-27, 1993		+-
+	{	C56	IVERSEN, et al., Antisense Research and Development, (1994), 4:43-52		+
+		C57	JAKOB, et al., Int. Arch Allergy Immunol., 118(2-4):457-61, 1999		+
+		C58	JAKOB, et al., J. Immunol., 161(6):3042-9, 1998		
+		C59	JOHNSON, et al. Immunopharmacol Infect Disease, 291-301, 1987		+
4	/	C60	JOHNSON, et al., Immunopharmacoi Inject Disease, 291-301, 1987		+
_\		C61	<u> </u>		
	DB_1		KATAOKA, et al., Jpn. J.Med. Sci. Bio., 43:171-189 (1990)	<u>-</u> _	
47.1			/ pr / /		
	to	en	Bahl 6/17/04		

/	<u></u>) ł	۲	E	2	
•	APR	0	7	2003	25	•
, A.		_	_		4	_

, M		<u>/</u>			
1	B.	€062	KERN, et al. Antimicrobial Agent Chemother. 7:793, 1975	1	
G TRA	10,000	C63	KIMURA Y et al., J. Biochem., 116(5):991-994, 1994		
		C64	KLOC, et al., "Interleukin-2 antisense oligonucleotides inhibit in vitro functions of T cells."		
	┼	C65	FASEB J., Vol. 5, pp. A973, abstract no. 3497, 1991.		
ļ		<u> </u>	KROWN, S.E., Semin Oncol., 13(2):207-17, 1986		
	4	C66	LEE, et al. Transplantation, 62:1297-1301, 1996		
		C67	LEVINE, et al. Cancer Treatment Repts. 62:1907, 1978		
		C68	LEVY, et al. J Infect Disease, 133:A256, 1976		
1		C69	LU, et al., Clin. Exp. Immunol., 115:335-341, 1999		
		C70	MACAYA, et al. Proc Natl Acad Sci USA 90:3745-9, 1993		
		C71	MASHIBA, et al., Jpn. J. Med. Sci. Biol., 41:197-202, 1988		
	1	C72	MASTRANGELO, et al., Seminars in Oncology. 23(1):4-21, Feb 1996		
	<u> </u>	C73	MATSON S and KRIEG AM, Antisense Res Dev 2(4):325-30, Winter 1992		
	<u>L</u>	C74	MATSUKURA, et al. Proc Natl Acad Sci USA 86:4244-48, 1989		
		C75	MESSINA et al., Cellular Immunology, 147(1):148-157, 1993		
		C76	NYCE and METZGER, Nature 385:721-725, 1997		
		C77	PARKER, et al. Cancer Gene Therapy. 3:175, 1996		
		C78	PETERSEN, et al., Bio. Pharm., 47(1):127-128, 1994		
		C79	PISETSKY DS, Antisense Res Dev, 5(3):219-225 (1995)		
		C80	PISETSKY DS, J Immunol 156(2):421-3, 1996		
		C81	POTTRATZ, et al., J. Clin. Invest., 93(3):944-50, 1994		
		C82	RAMANATHAN, et al. J Biol Chem 269:24565-74, 1994		
		C83	RAMANATHAN, et al. Transplantation, 57:612-15, 1994		
		C84	RAZ, et al., Proc Natl Acad Sci USA 93(10):5141-5, (1996)		
		C85	ROMAN M et al., Nat Med 3(8):849-54, (1997)		
		C86	ROUSH, et al. Science, 276:1193, 1997		
		C87	SATO et al., Science, 273:352-354, 1996		
		C88	SHIRAKAWA, et al., Science 275(5296):77-9, (1997)		
	-	C89	SIN, et al, J. of Virol., 73(1):501-509, 1999		
		C90	SIN, et al., J. of Immunol., 162:2912-2921, 1999		
	-	C91	STULL et al., Pharmaceutical Res., 12(4):465-483, 1995	1-1	
		C92	TALMADGE, et al., Cancer Res. 45(3):1058-65, 1985		
		C93	TSUJI, et al., J. of Immunol., 158:4008-4013, 1997		
	/	C94	WANG, et al. Proc. Natl Acad. Sci. USA, 90:4156-4160, 1993	$\neg \neg \neg$	
	/	C95	WILTROUT, et al., J. Biol. Res. Mod., 4(5):512-7, 1985		~
7	Ĺ	C96	WYATT, et al. Proc Natl Acad Sci USA, 91:1356-60, 1994		
يلت	<u> </u>	L	<u> </u>		

		· · · · · · · · · · · · · · · · · · ·	1				
EXAMINER	Tunl	Blohn		DATE CONSIDERED,	117	104	

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation-in-part, and divisional applications).

HECFIVED

JUN 0 5 2001

FORM PTO-1449(Modified)

LIST OF PATENTS AND PUBLICATIONS TEAM APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: C1039/7035 TEQH: CENTER 0560/2000

APPLICANT: Krieg, et al.

FILING DATE: September 25, 2000 GR

GROUP: 1646

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)	Class	Sub Class	Translatio Yes	n No

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

		(madding Addior, ritie, Date, Perditent Pages, Publication, Cit.)
DB C1		Kataoka, et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG", <i>Jpn. J. Cancer Res.</i> , 83:244-247 (1992)
	C2	Krieg, et al., "Editorial:Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?", Antisense Res. Devlp., 5:241 (1995)
	C3	Krieg, A.M., "Leukocyte stimulation by oligodeoxynucleotides", Applied Antisense Oligonucleotide Technology", 24:431-448 (1998)
	C4	Sun, et al., "Mitogenicity of DNA from different organisms for murine B cells", J. Immunol., 159:3119-3125 (1997)
	C5	Krieg, et al., "Brief Communication: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", Antisense Nucleic Acid. Drug Development, 6:133-139 (1996)
	C6	Messina, et al., "Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA", J. of Immunol., 147(6):1759-1764 (1991)
	C7	McIntyre, et al., "A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kB p65 causes sequence-specific immune stimulation", <i>Antisense Res. and Devlop.</i> , 3:309-322 (1993)
	C8	Hartmann, et al., "Mechanism and function of a newly identified CpG DNA motif in human primary b cells", J. of Immunol., 164:944-952 (2000)
	C9	Yi, et al., "CpG DNA rescues B cells from apoptosis by activating NFkB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway", International Immunol., 11(12):2015-2024 (1999)
(/	C10	Hartmann, et al., "Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo", J. of Immunol., 164:1617-1624 (2000)
DB	C11	Pisetsky, et al., "The influence of base sequence on the immunological properties of defined oligonucleotides", Immunopharmacology, 40:199-208 (1998)

536953.1

Faul Blild

6/17/04

		OITE TO	williangia c
	•	NIN 0 1 2001 E	
DB	C12	To Linguis and Marketic single-stranded DNA, poly(dG,dC), induces interferon-α/β activity, and suppresses tumor growth, Jpn. J. Cancer Res., 79:682-686 (1988)	
DB	C13	Tokunaga, et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells", <i>Jpn J. Cancer Res.</i> , 36(1):55-66 (1992)	
		RECEIVED	
		JUN 0 5 2001	
		TECH CENTER 1600/2900	
	·		
·			
EXAMIN	NER	and Block DATE CONSIDERED 6/17/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant